Talaris Therapeutics Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Mary Fenton
Chief Executive Officer (CEO)
US$2.2m
Compensación total
| Porcentaje del salario del CEO | 20.6% |
| Permanencia del CEO | 2.6yrs |
| Participación del CEO | 0.07% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?
May 24
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?
Feb 14We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Oct 21Talaris drops 24% after patient death in late-stage trial for lead asset
Oct 20Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Aug 29Talaris Therapeutics GAAP EPS of -$0.44
Aug 15We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Jul 06Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
Jun 30Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans
Mar 23Talaris Therapeutics EPS beats by $0.49
Jun 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$75m |
| Mar 31 2023 | n/a | n/a | -US$78m |
| Dec 31 2022 | US$2m | US$455k | -US$74m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$64m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$2m | US$340k | -US$48m |
Compensación vs. Mercado: La compensación total ($USD2.21M) de Mary está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Mary ha sido consistente con los resultados de la empresa en el último año.
CEO
Mary Fenton (59 yo)
2.6yrs
Permanencia
US$2,209,223
Compensación
Ms. Mary Kay Fenton has been Chief Financial Officer at Talaris Therapeutics, Inc. since March 2021 and serves as its Treasurer and has been its Interim CEO and President since May 26, 2023. She had been a...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 21.7yrs | US$1.33m | 11.88% $ 65.7m | |
| Independent Director | 4.9yrs | US$130.42k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$135.05k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$137.92k | 0% $ 0 | |
| Independent Chairman | 4.9yrs | US$175.92k | 0.90% $ 5.0m | |
| Independent Director | 4.9yrs | US$130.42k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$249.58k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$126.92k | 0% $ 0 |
4.9yrs
Permanencia media
56yo
Promedio de edad
Junta con experiencia: La junta directiva de TALS se considera experimentada (4.9 años de antigüedad promedio).